Clinical Research Division

  • Adair Lab
    Develops new gene therapy treatments and protocols for the treatment of many different genetic and infectious diseases
  • Bedalov Lab
    The Bedalov Lab conducts research to identify drugs that disrupt gene silencing, a process that has been implicated in cancer and other diseases in which genes are inappropriately shut off.
  • Bernstein Lab
    Dr. Irwin D. Bernstein's research interests include normal and leukemic hematopoietic stem cells, antibody targeted therapies for lymphoma and leukemia, and the biology of acute myeloid leukemia.
  • Biobehavioral Sciences
    The Biobehavioral Sciences program investigates mechanisms and methods for integrating behavioral and biological components of care for cancer survivors during and following active treatment.
  • Bleakley Lab
    Strategies to engineer hematopoietic stem cell grafts to prevent GVHD and augment graft-versus-leukemia in order to prevent relapse, adoptive T cell immunotherapy to augment graft-versus-leukemia and histocompatibility antigens as targets for future immunotherapy, graft engineering to manage relapse after transplant.
  • Clinical Biostatistics
    Clinical Biostatistics researchers collaborate in numerous inter-disciplinary projects across Fred Hutch and the Consortium. Their work contributes to Fred Hutch’s goal of translating discoveries into cures.
  • Clurman Lab
    The Clurman Lab studies how cell division is regulated in normal cells, and how abnormal control of cell division leads to cancer. They hope to use these mechanistic insights into tumor formation to develop new cancer treatment strategies.
  • Crohn's Allogeneic Transplant Study (CATS)
    A clinical study for treatment of patients with severe Crohn's Disease, using bone marrow transplantation. This study is being conducted by Dr. George McDonald and teams of doctors and nurses at the University of Washington Medical Center, Seattle Children's Hospital and the Fred Hutchinson Cancer Research Center in Seattle.
  • Delaney Lab
    The focus of the Delaney Lab is the development and clinical translation of methodologies for the ex vivo expansion of hematopoietic stem and progenitor cells. In particular, cord blood stem and progenitor cells with the goal of improving outcomes for patients undergoing cord blood transplantation.
  • Dudakov Lab
    The focus of the Dudakov lab is to elucidate the mechanisms underlying endogenous thymic regeneration so that they may be exploited into therapeutic strategies to boost immune function.
  • Green Lab
  • Greenberg Lab
    Research is focused on the immunobiology of viral and malignant diseases, and developing cellular and molecular strategies to manipulate T cell immunity for the treatment of human diseases.
  • GVHD Assessment Video
  • Hansen Lab
    The Hansen Lab's primary research focus is graft-vs.-host disease (GVHD). Ongoing studies investigate whether monitoring of gene expression correlates with T-cell activation, programmed cell death, severity of GVHD, the patient's response to primary therapy or treatment failure, and emergence of tolerance.
  • Heimfeld Lab
    The Heimfeld Lab focuses on the translation of new cell-based therapies from the scientist's bench to the patient's bedside. Areas of research include improvements in specific cell-subset selection, large-scale therapeutic-cell culturing in closed systems, optimized cryopreservation and cell storage.
  • Hingorani Lab
    Investigates the molecular and cellular mechanisms that drive the pathogenesis of pancreatic ductal adenocarcinoma (PDA) or, more commonly, pancreas cancer.
  • Immunology Study
    Fred Hutch is recruiting volunteers for a study focused on the development of new immunotherapy-based treatment. Study volunteers will go through a screening process to determine eligibility. Eligible donors are added to our database for study enrollment. Eligible donors will be invited to attend a blood draw donation event.
  • Institute for Prostate Cancer Research
    The institute is a collaborative effort of Fred Hutchinson Cancer Research Center and UW Medicine. A natural outgrowth of established research and clinical collaborations, the IPCR brings together a world-renowned team whose mission is to understand the causes of prostate cancer and its progression, develop new prevention strategies, devise innovative diagnostics and improve survival and quality of life.
  • J. Lee Nelson Lab
    The J. Lee Nelson Lab studies microchimerism, a natural state in which cells are exchanged between mother and fetus during pregnancy and can remain in the other individual decades later. They study the role of this phenomenon in autoimmune diseases, pregnancy complications and cancer, as well as its impact on the success of blood stem-cell and organ transplants.
  • Kiem Lab
    The Kiem Lab studies stem cell biology and stem cell gene transfer with the goal of developing new treatment strategies for patients with genetic and infectious diseases and cancers.
  • Lee Lab
    Our work focuses on hematopoietic stem cell transplant patients and chronic graft-versus-host disease (cGHVD). Dr. Lee is the lead investigator and Fred Hutchinson Cancer Research Center is the coordinating center for the Chronic Graft-versus-Host Disease Consortium within the Rare Diseases Clinical Research Network.
  • Long-Term Follow-Up
  • Lymphoma Program
  • Mendez Lab
    Our research is looking to discover which genes are related specifically to the spread of head and neck cancers to other parts of the body by comparing the genetics of tumors that have not spread with those that have. We hope to one day allow physicians to predict which tumors are more likely to spread, information that will, in turn, affect treatment decisions.
  • Oehler Lab
  • Olson Lab
    The Olson Lab studies pediatric brain tumors, brain development and neurodegenerative disorders. The lab has a strong focus on emergent technologies such as "tumor paint," which causes cancer cells to glow with light so that surgeons can see them during an operation.
  • Orozco Lab
    Focus on developing and improving antibody therapies for leukemia and lymphoma patients, with the goal of translating laboratory findings into the clinic and increasing the effectiveness of radioimmunotherapy by developing “pre-targeted” methods for more selectively delivering radiation to tumor sites.
  • Paulovich Lab
    The Paulovich Lab works to characterize human variation and to relate this variation to clinically relevant endpoints, such as predicting a patient's risk of cancer and tolerance for treatments. Projects range from studying cellular DNA damage response in yeast and mammalian cells, to developing novel mass spectrometry-based technologies for finding and validating new protein biomarkers to serve as diagnostic tests.
  • Pollack Lab
    The Pollack Lab is developing new ways to culture and engineer T cells with sarcoma specificity and learning how to overcome the inhibitory effects of the sarcoma tumor microenvironments on what might otherwise be effective immunotherapies
  • Press Lab
    Dr. Press is a pioneer in immunotherapy, a treatment strategy that harnesses the power of the immune system. His lab engineers antibodies that help to destroy cells involved in blood cancers and carry radiation directly to cancer cells. They also genetically modify disease-fighting T-cells to boost their ability to recognize and kill lymphoma cells.
  • Program in Immunology
    The Program in Immunology is focused on learning how immune cells respond to disease and how to safely enhance immunity to better control, cure and potentially prevent malignancies and many other serious conditions.
  • Radich Lab
    The Radich Lab studies the molecular genetics of response, progression and relapse in human leukemia. Research topics include the detection of minimal residual disease, the role of signal transduction abnormalities in leukemia, and the construction of gene-expression profiles of response and progression.
  • Research Cell Bank
    The Research Cell Bank (RCB) is a qualified, experienced research facility that has been actively engaged in clinical research through B-lymphoblastoid cell (B-LCL) transformation and maintenance, DNA extraction, and inventory control for more than 30 years. The RCB is currently expanding its role as a core repository of reagents and services to better serve the needs of investigators worldwide.
  • Riddell Lab
    Elucidating how T cells recognize cancer cells and pathogens and how to safely enhance T cell immunity to better control, cure and potentially prevent malignancies and serious viral infections.
  • Rongvaux Lab
    The Rongvaux Lab studies the innate immune response, the very first steps in the development of the immune response, after exposure to a pathogen or formation of a tumor.
  • Simon Lab
    Research is focused on the development of new anticancer drugs through a wide range of experimental techniques and systems, ranging from organic synthesis to genetic screens. The compounds being studied have been identified from large collections of synthetic, drug-like compounds and from natural sources.
  • Spies Lab
    The Spies Lab focuses on experimental studies of the human NKG2D lymphocyte receptor and its ligands, and the mechanisms whereby these proteins stimulate or suppress immune responses against cancer and in autoimmune disease.
  • Stem Cell Donor Study
    The Heimfeld Lab is seeking normal healthy volunteers 18 to 70 years of age to provide Peripheral Blood Mononuclear Cells (PBMC) for research. After donation, participants will receive compensation for their time and inconvenience. Learn more.
  • Stirewalt Lab
    The Stirewalt Lab is using AML as a prototype to explore the relationship of aging and malignant transformation, and how aging may be changing the biology of the hematopoietic diseases in older adults.
  • Storb Lab
    Transplantation Biology combines basic and translational research directed at understanding and eliminating major barriers to successful allogeneic hematopoietic stem cell transplantation; these include host-versus-graft reactions, graft failure, acute and chronic graft-versus-host disease (GVHD), regimen-related toxicities, and induction of graft-versus-tumor reactions. The program’s goal has been to use stem cell transplantation to treat patients with malignant and nonmalignant hematologic diseases.
  • Survivorship Program
    Fred Hutchinson Cancer Research Center's Survivorship Program offers support, treatment and education to cancer survivors. A member of the LIVESTRONG Survivorship Center of Excellence Network, the Survivorship Program is helping to lead a nationwide effort to help survivors and their healthcare providers understand, prevent and manage the medical and psychosocial effects of having cancer and receiving treatment.
  • Till Lab
    Translational research on chimeric antigen receptor (CAR) T cells and assessing the function of CAR T cells targeting CD20 and CD19 in vitro and in mouse models, including correlative assays investigating the development of endogenous anti-tumor immune responses following CAR T cell therapy
  • Tumor Vaccine Group
  • Turtle Lab
    The Turtle Laboratory in the Fred Hutch Program in Immunology is focused on understanding the characteristics of distinct subsets of human T cell subsets, their potential utility for tumor immunotherapy and their role in immune reconstitution after HCT.
  • Walter Lab
    Research is focused on clinical trials testing new drugs and drug combinations to treat acute myeloid leukemia.
  • Warren Lab
    The Warren Lab studies human antitumor immune responses at the cellular and molecular level in order to learn how these immune responses can be exploited to treat human cancer.

Find a lab or project in Clinical Research